Literature DB >> 24535544

Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets?

John Varga1, Monique Hinchcliff1.   

Abstract

Patients with systemic sclerosis present with varying clinical features, have different responses to therapy, and end up with different outcomes. Categorizing patients improves disease management. A new study now proposes that patients with systemic sclerosis and overlapping features of another connective tissue disease might form a distinct disease subset.

Entities:  

Mesh：

Year:  2014        PMID： 24535544      PMCID： PMC5438483          DOI： 10.1038/nrrheum.2014.22

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.

Authors:  Olivier C Meyer; Noreen Fertig; Mary Lucas; Nathalie Somogyi; Thomas A Medsger
Journal:  J Rheumatol       Date:  2006-11-15       Impact factor: 4.666

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Association of the autoimmune disease scleroderma with an immunologic response to cancer.

Authors:  Christine G Joseph; Erika Darrah; Ami A Shah; Andrew D Skora; Livia A Casciola-Rosen; Fredrick M Wigley; Francesco Boin; Andrea Fava; Chris Thoburn; Isaac Kinde; Yuchen Jiao; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Antony Rosen
Journal:  Science       Date:  2013-12-05       Impact factor: 47.728

4.  Clinical and serological hallmarks of systemic sclerosis overlap syndromes.

Authors:  Angela Pakozdi; Svetlana Nihtyanova; Pia Moinzadeh; Voon H Ong; Carol M Black; Christopher P Denton
Journal:  J Rheumatol       Date:  2011-08-15       Impact factor: 4.666

5.  Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients.

Authors:  H Poormoghim; M Lucas; N Fertig; T A Medsger
Journal:  Arthritis Rheum       Date:  2000-02

6.  Antinuclear antibodies and clinical associations in a british cohort with limited cutaneous systemic sclerosis.

Authors:  Angela E Gliddon; Caroline J Doré; Juliet Dunphy; Zoë Betteridge; Neil J McHugh; Peter J Maddison
Journal:  J Rheumatol       Date:  2011-01-15       Impact factor: 4.666

7.  Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort.

Authors:  Roberta Gonçalves Marangoni; Luiza Fuoco Rocha; Ana Paula T Del Rio; Natalino H Yoshinari; João Francisco Marques-Neto; Percival D Sampaio-Barros
Journal:  Rheumatology (Oxford)       Date:  2013-05-09       Impact factor: 7.580

8.  Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.

Authors:  Pia Moinzadeh; Elisabeth Aberer; Keihan Ahmadi-Simab; Norbert Blank; Joerg H W Distler; Gerhard Fierlbeck; Ekkehard Genth; Claudia Guenther; Ruediger Hein; Joerg Henes; Lena Herich; Ilka Herrgott; Ina Koetter; Alexander Kreuter; Thomas Krieg; Kathrin Kuhr; Hanns-Martin Lorenz; Florian Meier; Inga Melchers; Hartwig Mensing; Ulf Mueller-Ladner; Christiane Pfeiffer; Gabriela Riemekasten; Miklós Sárdy; Marc Schmalzing; Cord Sunderkoetter; Laura Susok; Ingo H Tarner; Peter Vaith; Margitta Worm; Gottfried Wozel; Gabriele Zeidler; Nicolas Hunzelmann
Journal:  Ann Rheum Dis       Date:  2014-01-03       Impact factor: 19.103

9.  Molecular subsets in the gene expression signatures of scleroderma skin.

Authors:  Ausra Milano; Sarah A Pendergrass; Jennifer L Sargent; Lacy K George; Timothy H McCalmont; M Kari Connolly; Michael L Whitfield
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

10.  Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis.

Authors:  Monique Hinchcliff; Chiang-Ching Huang; Tammara A Wood; J Matthew Mahoney; Viktor Martyanov; Swati Bhattacharyya; Zenshiro Tamaki; Jungwha Lee; Mary Carns; Sofia Podlusky; Arlene Sirajuddin; Sanjiv J Shah; Rowland W Chang; Robert Lafyatis; John Varga; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2013-03-14       Impact factor: 8.551
  10 in total
  8 in total

1.  The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib.

Authors:  Wenxia Wang; Swati Bhattacharyya; Roberta Goncalves Marangoni; Mary Carns; Kathleen Dennis-Aren; Anjana Yeldandi; Jun Wei; John Varga
Journal:  J Scleroderma Relat Disord       Date:  2019-08-07

Review 2.  Update on scleroderma-associated interstitial lung disease.

Authors:  Ming-Hui Fan; Carol A Feghali-Bostwick; Richard M Silver
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

3.  TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung.

Authors:  Swati Bhattacharyya; Wenxia Wang; Wenyi Qin; Kui Cheng; Sara Coulup; Sherry Chavez; Shuangshang Jiang; Kirtee Raparia; Lucia Maria V De Almeida; Christian Stehlik; Zenshiro Tamaki; Hang Yin; John Varga
Journal:  JCI Insight       Date:  2018-07-12

Review 4.  Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance.

Authors:  Benjamin D Korman; Lindsey A Criswell
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

5.  Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.

Authors:  Vincent Sobanski; Jonathan Giovannelli; Yannick Allanore; Gabriela Riemekasten; Paolo Airò; Serena Vettori; Franco Cozzi; Oliver Distler; Marco Matucci-Cerinic; Christopher Denton; David Launay; Eric Hachulla
Journal:  Arthritis Rheumatol       Date:  2019-08-12       Impact factor: 10.995

6.  The Enlargement of Abdominal Lymph Nodes Is a Characteristic of Autoimmune Liver Disease.

Authors:  Yongjuan Wang; Xiuxiu Xu; Maojuan Ran; Xiaopei Guo; Lu Zhou; Xi Wang; Bangmao Wang; Jie Zhang
Journal:  Mediators Inflamm       Date:  2020-03-21       Impact factor: 4.711

Review 7.  Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development.

Authors:  Andrea De Pieri; Benjamin D Korman; Astrid Jüngel; Karin Wuertz-Kozak
Journal:  Adv Biol (Weinh)       Date:  2021-02-15

8.  Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis.

Authors:  Pierpaolo Palumbo; Piero Ruscitti; Paola Cipriani; Ernesto Di Cesare; Ester Cannizzaro; Onorina Berardicurti; Alessandro Conforti; Annamaria Di Cesare; Ilenia Di Cola; Roberto Giacomelli; Alessandra Splendiani; Antonio Barile; Carlo Masciocchi
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.